1. McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The FLS: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034
2. National Institute for Health and Clinical Excellence. (2008a) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Guidance and Assessment Report No. 160. http://www.nice.org.uk/nicemedia/pdf/Assessment_report_osteo.pdf . Accessed 14 September 2009
3. National Institute for Health and Clinical Excellence. (2008b) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Guidance and Assessment Report No. 161. http://www.nice.org.uk/nicemedia/pdf/Osteo%20_AR.pdf . Accessed 14 September 2009
4. Royal College of Physicians. (1999) Osteoporosis: clinical guidelines for prevention and treatment. http://www.rcplondon.ac.uk/Pubs/brochure.aspx?e=136 . Accessed 24 September 2009
5. Scottish Intercollegiate Guidelines Network. (2003) Guideline 71: management of osteoporosis. http://www.sign.ac.uk/pdf/sign71.pdf . Accessed 24 September 2009